All Stories

  1. Targeting the p53 cancer mutants Y220C, Y220N, and Y220S with the small-molecule stabilizer rezatapopt

    Article • Cell Death and Disease, February 2026, Springer Science + Business Media

    Dr Andreas C Joerger

  2. Enantioselective protein affinity selection mass spectrometry (E-ASMS)

    Article • Nature Communications, December 2025, Springer Science + Business Media

    Mr CONRAD SIMOBEN VERANSO, Dr Andreas C Joerger

  3. Structural analysis of TRIM family PRYSPRY domains and its implications for E3-ligand design

    Article • Journal of Structural Biology X, December 2025, Elsevier

    Dr Andreas C Joerger

  4. Structure-Guided Design of ISOX-DUAL-Based Degraders Targeting BRD4 and CBP/EP300: A Case of Degrader Collapse

    Article • Journal of Medicinal Chemistry, April 2025, American Chemical Society (ACS)

    Dr Andreas C Joerger

  5. DARPin-induced reactivation of p53 in HPV-positive cells

    Article • Nature Structural & Molecular Biology, January 2025, Springer Science + Business Media

    Dr Andreas C Joerger

  6. Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations

    Article • Nature Genetics, January 2025, Springer Science + Business Media

    Dr Andreas C Joerger

  7. TP53: the unluckiest of genes?

    Article • Cell Death and Differentiation, October 2024, Springer Science + Business Media

    Dr Andreas C Joerger

  8. Back-Pocket Optimization of 2-Aminopyrimidine-Based Macrocycles Leads to Potent EPHA2/GAK Kinase Inhibitors

    Article • Journal of Medicinal Chemistry, July 2024, American Chemical Society (ACS)

    Dr Andreas C Joerger

  9. Structural basis of p53 inactivation by cavity-creating cancer mutations and its implications for the development of mutant p53 reactivators

    Article • Cell Death and Disease, June 2024, Springer Science + Business Media

    Dr Andreas C Joerger

  10. Development of Selective Pyrido[2,3-d]pyrimidin-7(8H)-one-Based Mammalian STE20-Like (MST3/4) Kinase Inhibitors

    Article • Journal of Medicinal Chemistry, February 2024, American Chemical Society (ACS)

    Dr Andreas C Joerger

  11. Development of Potent Dual BET/HDAC Inhibitors via Pharmacophore Merging and Structure-Guided Optimization

    Article • ACS Chemical Biology, January 2024, American Chemical Society (ACS)

    Dr Andreas C Joerger

  12. Synthesis of Pyrazole-Based Macrocycles Leads to a Highly Selective Inhibitor for MST3

    Article • Journal of Medicinal Chemistry, December 2023, American Chemical Society (ACS)

    Dr Andreas C Joerger

  13. From cultivation to cancer: formation of N -nitrosamines and other carcinogens in smokeless tobacco and their mutagenic implications

    Article • Critical Reviews in Toxicology, November 2023, Taylor & Francis

    Dr Andreas C Joerger

  14. Structure–Reactivity Studies of 2-Sulfonylpyrimidines Allow Selective Protein Arylation

    Article • Bioconjugate Chemistry, September 2023, American Chemical Society (ACS)

    Dr Andreas C Joerger

  15. Development of potent dual BET/HDAC inhibitorsviapharmacophore merging and structure-guided optimization

    Article • July 2023, Cold Spring Harbor Laboratory Press

    Dr Andreas C Joerger

  16. Structural insights into a regulatory mechanism of FIR RRM1–FUSE interaction

    Article • Open Biology, May 2023, Royal Society Publishing

    Dr Andreas C Joerger

  17. Shifting the selectivity of pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors towards the salt-inducible kinase (SIK) subfamily

    Article • March 2023, Cold Spring Harbor Laboratory Press

    Dr Andreas C Joerger

  18. Development of a Potent Cyclic Peptide Inhibitor of the nNOS/PSD-95 Interaction

    Article • Journal of Medicinal Chemistry, December 2022, American Chemical Society (ACS)

    Dr Andreas C Joerger

  19. Discovery of Nanomolar-Affinity Pharmacological Chaperones Stabilizing the Oncogenic p53 Mutant Y220C

    Article • ACS Pharmacology & Translational Science, October 2022, American Chemical Society (ACS)

    Dr Andreas C Joerger

  20. Evolutionary history of the p53 family DNA-binding domain: insights from an Alvinella pompejana homolog

    Article • Cell Death and Disease, March 2022, Springer Science + Business Media

    Dr Andreas C Joerger

  21. Development of a Selective Dual Discoidin Domain Receptor (DDR)/p38 Kinase Chemical Probe

    Article • Journal of Medicinal Chemistry, September 2021, American Chemical Society (ACS)

    Dr Andreas C Joerger

  22. Structure-Based Design of Selective Salt-Inducible Kinase Inhibitors

    Article • Journal of Medicinal Chemistry, June 2021, American Chemical Society (ACS)

    Dr Andreas C Joerger

  23. Exploiting vulnerabilities of SWI/SNF chromatin remodelling complexes for cancer therapy

    Article • Oncogene, May 2021, Springer Science + Business Media

    Dr Andreas C Joerger

  24. Structure-based design of selective salt-inducible kinase (SIK) inhibitors

    Article • April 2021, Cold Spring Harbor Laboratory Press

    Dr Andreas C Joerger

  25. Genotoxicity and Epigenotoxicity of Carbazole-Derived Molecules on MCF-7 Breast Cancer Cells

    Article • International Journal of Molecular Sciences, March 2021, MDPI AG

    Dr Andreas C Joerger

  26. Integrated analysis of Shank1 PDZ interactions with C-terminal and internal binding motifs

    Article • Current Research in Structural Biology, January 2021, Elsevier

    Dr Andreas C Joerger

  27. Selective targeting of the αC and DFG-out pocket in p38 MAPK

    Article • European Journal of Medicinal Chemistry, December 2020, Elsevier

    Dr Andreas C Joerger

  28. Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene

    Article • Cell Death and Differentiation, November 2020, Springer Science + Business Media

    Dr Andreas C Joerger

  29. Pan-SMARCA/PB1 Bromodomain Inhibitors and Their Role in Regulating Adipogenesis

    Article • Journal of Medicinal Chemistry, November 2020, American Chemical Society (ACS)

    Dr Andreas C Joerger

  30. Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma

    Article • International Journal of Cancer, June 2020, Wiley

    Dr Andreas C Joerger

  31. Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm

    Article • ACS Chemical Biology, January 2020, American Chemical Society (ACS)

    Dr Andreas C Joerger

  32. A Structure-Guided Molecular Chaperone Approach for Restoring the Transcriptional Activity of the p53 Cancer Mutant Y220C

    Article • Future Medicinal Chemistry, October 2019, Taylor & Francis

    Dr Andreas C Joerger

  33. New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis

    Article • European Journal of Medicinal Chemistry, March 2019, Elsevier

    Dr Andreas C Joerger

  34. Extending the Code of Sequence Readout by Gene Regulatory Proteins: The Role of Hoogsteen Base Pairing in p53-DNA Recognition

    Article • Structure, September 2018, Elsevier

    Dr Andreas C Joerger

  35. Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines

    Article • European Journal of Medicinal Chemistry, May 2018, Elsevier

    Dr Andreas C Joerger

  36. Design of a molecular support for cryo-EM structure determination

    Article • Proceedings of the National Academy of Sciences, November 2016, Proceedings of the National Academy of Sciences

    Dr Andreas C Joerger

  37. 2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells

    Article • Proceedings of the National Academy of Sciences, August 2016, Proceedings of the National Academy of Sciences

    Dr Andreas C Joerger

  38. Harnessing Fluorine–Sulfur Contacts and Multipolar Interactions for the Design of p53 Mutant Y220C Rescue Drugs

    Article • ACS Chemical Biology, June 2016, American Chemical Society (ACS)

    Dr Andreas C Joerger

  39. The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches

    Article • Annual Review of Biochemistry, June 2016, Annual Reviews

    Sir Alan R Fersht, Dr Andreas C Joerger

  40. Exploiting Transient Protein States for the Design of Small-Molecule Stabilizers of Mutant p53

    Article • Structure, December 2015, Elsevier

    Dr Andreas C Joerger

  41. Experimental and Theoretical Evaluation of the Ethynyl Moiety as a Halogen Bioisostere

    Article • ACS Chemical Biology, October 2015, American Chemical Society (ACS)

    Dr Andreas C Joerger

  42. Tracing the Evolution of the p53 Tetramerization Domain

    Article • Structure, September 2014, Elsevier

    Dr Andreas C Joerger

  43. Pathological Unfoldomics of Uncontrolled Chaos: Intrinsically Disordered Proteins and Human Diseases

    Article • Chemical Reviews, May 2014, American Chemical Society (ACS)

    Dr Andreas C Joerger

  44. Halogen-Enriched Fragment Libraries as Chemical Probes for Harnessing Halogen Bonding in Fragment-Based Lead Discovery

    Article • Future Medicinal Chemistry, April 2014, Taylor & Francis

    Dr Andreas C Joerger

  45. Small molecule induced reactivation of mutant p53 in cancer cells

    Article • Nucleic Acids Research, April 2013, Oxford University Press (OUP)

    Dr Andreas C Joerger

  46. Principles and Applications of Halogen Bonding in Medicinal Chemistry and Chemical Biology

    Article • Journal of Medicinal Chemistry, January 2013, American Chemical Society (ACS)

    Dr Andreas C Joerger

  47. Evaluating Drosophila p53 as a Model System for Studying Cancer Mutations

    Article • Journal of Biological Chemistry, December 2012, Elsevier

    Dr Andreas C Joerger

  48. Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2

    Article • Proceedings of the National Academy of Sciences, October 2012, Proceedings of the National Academy of Sciences

    Dr Andreas C Joerger

  49. Halogen-Enriched Fragment Libraries as Leads for Drug Rescue of Mutant p53

    Article • Journal of the American Chemical Society, April 2012, American Chemical Society (ACS)

    Dr Andreas C Joerger

  50. Structure and Kinetic Stability of the p63 Tetramerization Domain

    Article • Journal of Molecular Biology, January 2012, Elsevier

    Dr Andreas C Joerger

  51. Interaction of the p53 DNA-Binding Domain with Its N-Terminal Extension Modulates the Stability of the p53 Tetramer

    Article • Journal of Molecular Biology, June 2011, Elsevier

    Dr Andreas C Joerger

  52. Acetylation of lysine 120 of p53 endows DNA-binding specificity at effective physiological salt concentration

    Article • Proceedings of the National Academy of Sciences, April 2011, Proceedings of the National Academy of Sciences

    Dr Andreas C Joerger

  53. Electrocatalytic Monitoring of Metal Binding and Mutation-Induced Conformational Changes in p53 at Picomole Level

    Article • Journal of the American Chemical Society, April 2011, American Chemical Society (ACS)

    Dr Andreas C Joerger

  54. Electron microscopy studies on the quaternary structure of p53 reveal different binding modes for p53 tetramers in complex with DNA

    Article • Proceedings of the National Academy of Sciences, December 2010, Proceedings of the National Academy of Sciences

    Dr Andreas C Joerger

  55. Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding

    Article • Protein Science, November 2010, Wiley

    Dr Andreas C Joerger

  56. The structure of the FYR domain of transforming growth factor beta regulator 1

    Article • Protein Science, June 2010, Wiley

    Dr Andreas C Joerger

  57. Protein Evolution via Amino Acid and Codon Elimination

    Article • PLOS One, April 2010, PLOS

    Michael Ibba, Dr Andreas C Joerger

  58. The Tumor Suppressor p53: From Structures to Drug Discovery

    Article • Cold Spring Harbor Perspectives in Biology, February 2010, Cold Spring Harbor Laboratory Press

    Dr Andreas C Joerger

  59. Molecular basis of S100 proteins interacting with the p53 homologs p63 and p73

    Article • Oncogene, February 2010, Springer Science + Business Media

    Dr Andreas C Joerger

  60. Toward the Rational Design of p53-Stabilizing Drugs: Probing the Surface of the Oncogenic Y220C Mutant

    Article • Chemistry & Biology, January 2010, Elsevier

    Dr Andreas C Joerger

  61. Conservation of DNA-binding specificity and oligomerisation properties within the p53 family

    Article • BMC Genomics, December 2009, Springer Science + Business Media

    Dr Andreas C Joerger

  62. Structural evolution of p53, p63, and p73: Implication for heterotetramer formation

    Article • Proceedings of the National Academy of Sciences, October 2009, Proceedings of the National Academy of Sciences

    Dr Andreas C Joerger

  63. Stabilising the DNA-binding domain of p53 by rational design of its hydrophobic core

    Article • Protein Engineering Design and Selection, June 2009, Oxford University Press (OUP)

    Dr Andreas C Joerger

  64. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug

    Article • Proceedings of the National Academy of Sciences, July 2008, Proceedings of the National Academy of Sciences

    Dr Andreas C Joerger

  65. Structural Biology of the Tumor Suppressor p53

    Article • Annual Review of Biochemistry, June 2008, Annual Reviews

    Dr Andreas C Joerger

  66. Correlation of Levels of Folded Recombinant p53 in Escherichia coli with Thermodynamic Stability in Vitro

    Article • Journal of Molecular Biology, September 2007, Elsevier

    Dr Andreas C Joerger

  67. Structure–function–rescue: the diverse nature of common p53 cancer mutants

    Article • Oncogene, April 2007, Springer Science + Business Media

    Dr Andreas C Joerger

  68. Structural Biology of the Tumor Suppressor p53 and Cancer‐Associated Mutants

    Article • January 2007, Elsevier

    Dr Andreas C Joerger

  69. Structural basis for understanding oncogenic p53 mutations and designing rescue drugs

    Article • Proceedings of the National Academy of Sciences, October 2006, Proceedings of the National Academy of Sciences

    Dr Andreas C Joerger

  70. Effects of Common Cancer Mutations on Stability and DNA Binding of Full-length p53 Compared with Isolated Core Domains

    Article • Journal of Biological Chemistry, August 2006, Elsevier

    Dr Andreas C Joerger

  71. Structures of p53 Cancer Mutants and Mechanism of Rescue by Second-site Suppressor Mutations

    Article • Journal of Biological Chemistry, April 2005, Elsevier

    Dr Andreas C Joerger

  72. Crystal Structure of a Superstable Mutant of Human p53 Core Domain

    Article • Journal of Biological Chemistry, January 2004, Elsevier

    Dr Andreas C Joerger

  73. Mimicking natural evolution in vitro : An N -acetylneuraminate lyase mutant with an increased dihydrodipicolinate synthase activity

    Article • Proceedings of the National Academy of Sciences, April 2003, Proceedings of the National Academy of Sciences

    Dr Andreas C Joerger

  74. Structures of l -fuculose-1-phosphate aldolase mutants outlining motions during catalysis 1 1Edited by I. A. Wilson

    Article • Journal of Molecular Biology, November 2000, Elsevier

    Dr Andreas C Joerger

  75. Catalytic Action of Fuculose 1-Phosphate Aldolase (Class II) As Derived from Structure-Directed Mutagenesis,

    Article • Biochemistry, April 2000, American Chemical Society (ACS)

    Dr Andreas C Joerger